Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

• Published in: The New England journal of medicine Vol. 378; no. 12; pp. 1107 - 1120
• Main Authors: Seymour, John F, Kipps, Thomas J, Eichhorst, Barbara, Hillmen, Peter, D’Rozario, James, Assouline, Sarit, Owen, Carolyn, Gerecitano, John, Robak, Tadeusz, De la Serna, Javier, Jaeger, Ulrich, Cartron, Guillaume, Montillo, Marco, Humerickhouse, Rod, Punnoose, Elizabeth A, Li, Yan, Boyer, Michelle, Humphrey, Kathryn, Mobasher, Mehrdad, Kater, Arnon P
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 22.03.2018
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bendamustine Hydrochloride - administration & dosage; Bendamustine Hydrochloride - adverse effects; Bone marrow; Bridged Bicyclo Compounds, Heterocyclic - administration & dosage; Bridged Bicyclo Compounds, Heterocyclic - adverse effects; Cancer therapies; Chemotherapy; Chromosome 17; Chromosome deletion; Chromosomes; Chronic lymphocytic leukemia; Clinical trials; Clonal deletion; Disease-Free Survival; Drug dosages; Drug Resistance, Neoplasm; Evidence-based medicine; Female; Hematology; Humans; Immunotherapy; Kaplan-Meier Estimate; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; Leukemia, Lymphocytic, Chronic, B-Cell - mortality; Life Sciences; Lymphatic leukemia; Lysis; Male; Middle Aged; Monoclonal antibodies; Neoplasm, Residual; Neutropenia; Neutropenia - chemically induced; Oncology; Patients; Recurrence; Response rates; Rituximab; Rituximab - administration & dosage; Rituximab - adverse effects; Sulfonamides - administration & dosage; Sulfonamides - adverse effects; Targeted cancer therapy; Tumor Lysis Syndrome - etiology; Young Adult; Australia; United States > US; California; Recurrence; Lymphocytic; Humans; Middle Aged; Leukemia; Male; Residual; 80 and over; Young Adult; B-Cell; Female; Adult; Tumor Lysis Syndrome; Heterocyclic; Drug Resistance; Neutropenia; Kaplan-Meier Estimate; Rituximab; Antineoplastic Combined Chemotherapy Protocols; Neoplasm; Disease-Free Survival; Chronic; Bendamustine Hydrochloride; Sulfonamides; Aged; Bridged Bicyclo Compounds
• ISSN: 0028-4793; 1533-4406; 1533-4406
• DOI: 10.1056/NEJMoa1713976

In a trial involving patients with relapsed or refractory chronic lymphocytic leukemia, the BCL2 inhibitor venetoclax in combination with rituximab resulted in a higher 2-year rate of progression-free survival than bendamustine in combination with rituximab (85% vs. 36%).